<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-159361</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Frontal fibrosing alopecia: a pathology on the rise</dc:title>
<dc:description xml:lang="en">Frontal fibrosing alopecia (FFA) is a scarring alopecia whose incidence is increasing significantly in our country. It is characterized by loss of frontotemporal hairline that mostly affects postmenopausal women, with a negative impact on quality of life. It is associated with early menopause in 14% of cases and hypothyroidism in 15%. With regard to treatment, 5&amp;#945;-reductase inhibitors are the drugs that have shown improvement of the disease in a larger number of cases. We report a new case of FFA in a woman of 77 years successfully treated with finasteride at doses of 2.5mg daily (AU)</dc:description>
<dc:creator>Piris-García, X</dc:creator>
<dc:creator>Hierro-Cámara, M</dc:creator>
<dc:creator>Quintana-Sancho, A de</dc:creator>
<dc:creator>Valle-García, N</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La alopecia frontal fibrosante (AFF) es un tipo de alopecia cicatricial cuya incidencia está aumentando de forma significativa en nuestro país. Se caracteriza por un retroceso en la línea de implantación del pelo a nivel frontotemporal que afecta mayoritariamente a mujeres postmenopaúsicas, con un impacto negativo en su calidad de vida. Se asocia a menopausia precoz en un 14% de los casos y a hipotiroidismo en un 15%. Con respecto al tratamiento, son los inhibidores de la 5&amp;#945;-reductasa, los fármacos que han demostrado mejoría de la enfermedad en un mayor número de casos. Presentamos un caso de AFF en una mujer de 77 años tratada con éxito con finasteride a dosis de 2,5mg/día (AU)</dc:description>
<dc:source>An Sist Sanit Navar;39(3): 443-446, sept.-dic. 2016. ilus</dc:source>
<dc:identifier>ibc-159361</dc:identifier>
<dc:title xml:lang="es">Alopecia frontal fibrosante: una enfermedad en auge</dc:title>
<dc:subject>^d31467^s22073</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d11976^s22012</dc:subject>
<dc:subject>^d11976^s22067</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d508^s22057</dc:subject>
<dc:subject>^d54129^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d508^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201612</dc:date>
</metadata>
</record>
</ibecs-document>
